--- title: "3 Penny Stocks To Buy With Just $50" description: "This article discusses three penny stocks to consider for investment: Oatly, Precigen, and Gossamer Bio. Oatly, a Swedish company specializing in oat-based products, has a positive growth outlook with" type: "news" locale: "en" url: "https://longbridge.com/en/news/214377799.md" published_at: "2024-09-15T11:54:35.000Z" --- # 3 Penny Stocks To Buy With Just $50 > This article discusses three penny stocks to consider for investment: Oatly, Precigen, and Gossamer Bio. Oatly, a Swedish company specializing in oat-based products, has a positive growth outlook with a median price target of $2.70. Precigen, a clinical-stage biotech firm, is involved in multiple clinical trials and has a promising growth potential. Gossamer Bio focuses on a single product for pulmonary arterial hypertension and is entering Phase 3 trials, indicating potential for commercialization. The article emphasizes the high risks associated with penny stocks but acknowledges their potential for significant returns. Penny stocks are an interesting category. While they have the potential to produce significant long-run gains, you should never bet money on these stocks that you can’t afford to lose. After all, these are typically young and unprofitable companies. Approximately nine out of 10 of these companies will ultimately fail. On the other hand, if you buy a penny stock that succeeds in the long run, the gains you experience can be tremendous. While you shouldn’t break the bank to bet on penny stocks, there’s nothing wrong with making small bets if you have disposable income to risk. So if you’ve got $50 you can risk on penny stocks, which stocks should you buy? Here are a few to consider: **Key Points**: - Penny stocks can produce significant returns, but it’s important to consider the risks. - Oatly has the potential to nearly double in value over the next year with its oat milk-based products. - Precigen has several catalysts ahead with multiple ongoing clinical trials. - Gossamer Bio is a singular-focused biotech company that has the potential to produce significant returns. - If you want to buy low and sell high, you need to read our new Discover “the Next NVIDIA” report. We’ll outline two stocks that we believe will grow 10X or more. Don’t miss out; it’s free! ## Oatly Is a Strong Consumer Goods Play Oatly (Nasdaq: OTLY) is a Swedish consumer goods company that’s focused on plant-based milk and dairy products. As its name suggests, the company produces milk, cream cheese, frozen desserts, and soft-serve ice cream from oats. This offers multiple advantages: - Lactose-intolerant consumers can consume oat milk and dairy products. - These products typically have a lower environmental impact on land and water sources than dairy produced from cows. - Finally, the plants the company grows to produce its milk have a positive impact on the environment, filtering greenhouse gasses that would otherwise be produced by livestock. Analysts have a relatively positive opinion of the company too. Nine of them have weighed in on the stock with their ratings being evenly spread across “Buy,” “Outperform,” and “Hold,” with three ratings in each category. Moreover, the median price target on the stock is $1.70. Considering the current price of under $0.90 per share, the price target sets the stage for tremendous growth over the next year. ## Precigen Could Produce Significant Growth Ahead Precigen (Nasdaq: PGEN) is a clinical-stage biotechnology company. As a clinical-stage company, Precigen hasn’t brought any products to market yet, but that may change soon. Moreover, with a robust pipeline of drug candidates, a steady stream of data releases could keep this stock moving upward. In particular, the company has four ongoing Phase 2 clinical trials and three Phase 1 clinical trials. It’s using these trials to test candidates as potential treatment options for conditions like cancer, diabetes, and other debilitating ailments. The company also has two subsidiaries. Precigen ActoBio is a clinical-stage biotechnology company that’s working to develop microbe-based biologics. Exemplar Genetics, another subsidiary of Precigen is a discovery and research platform that helps scientists form an understanding of human disease mechanisms. All told, analysts are expecting significant growth out of Precigen. Four analysts have shared opinions. One rates the stock a “Buy,” two rate it an “Outperform,” and one rates it an “Underperform.” Between the four, the median price target is $7 per share. Not bad for a stock that’s trading for less than $1 per share right now. ## Gossamer Bio Is Another Biotech Play Poised for Growth Gossamer Bio (Nasdaq: GOSS) is another clinical-stage biotechnology company. However, rather than focusing on multiple potential products for use across a wide range of indications, the company is focused on the development and production of a single product, seralutinib. The product is being studied for the treatment of pulmonary arterial hypertension. The good news is that the company is moving into Phase 3 clinical trials. In fact, patients are being enrolled in the trial now. That’s important because Phase 3 is typically the final trial needed to submit a new drug application (NDA) to the FDA. If things go well, the company could move toward commercialization relatively soon. With the company on the verge of a potential NDA, any news surrounding its Phase 3 clnical trial of seralutinib could send the stock up. So any announcements surrounding the completion of enrollment in the trial, the commencement of the trial, and any trial data could act as a catalyst, sending the stock for the top. Perhaps that’s why analysts seem to be so excited about the stock. 10 analysts have shared opinions of GOSS, four rating the stock a “Buy”, three an “Outperform,” and three have rated it a “Hold.” And with a median price target of $7 per share, there’s likely plenty of room for growth. ## “The Next NVIDIA” Could Change Your Life If you missed out on NVIDIA’s historic run, your chance to see life-changing profits from AI isn’t over. The 24/7 Wall Street Analyst who first called NVIDIA’s AI-fueled rise in 2009 just published a brand-new research report named “The Next NVIDIA.” Click here to download your FREE copy. The post 3 Penny Stocks To Buy With Just $50 appeared first on 24/7 Wall St.. ### Related Stocks - [PGEN.US - Precigen](https://longbridge.com/en/quote/PGEN.US.md) - [GOSS.US - Gossamer Bio](https://longbridge.com/en/quote/GOSS.US.md) - [OTLY.US - Oatly Group AB](https://longbridge.com/en/quote/OTLY.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Binero 集团报告 2023 年下半年息税折旧摊销前利润为 1160 万瑞典克朗 | Binero Group AB（公开发行）: H2 净销售额为 2.518 亿瑞典克朗（2.123 亿）H2 EBITDA 为 1160 万瑞典克朗（1040 万）提议 2025 年不支付股息 | [Link](https://longbridge.com/en/news/276420609.md) | | Stillfront 的主要股东在特别会议上寻求更换董事会和主席 | Stillfront Group AB 的两大股东 Laureus Capital GmbH 和 Knuth Capital LLC FZ 持有约 23% 的股份，已请求召开临时股东大会以选举新董事会和董事长。提议的新董事长是 Lars-J | [Link](https://longbridge.com/en/news/276010342.md) | | 华尔街对麦克森股票的态度是看涨还是看跌？ | 华尔街对麦克森股票的看法是看涨还是看跌？ | [Link](https://longbridge.com/en/news/276144196.md) | | 帖子声称，记录显示麦康奈尔和凯文·麦卡锡讨论了 “恢复奴隶制”。但没有证据支持这一说法 | 一份声称是参议员米奇·麦康奈尔与前众议院议长凯文·麦卡锡之间电话通话的记录，声称他们讨论了恢复奴隶制和其他有争议的话题，但被认为没有根据。Snopes 未发现任何可信证据支持该记录或通话的真实性。这些说法在社交媒体上流传，但没有可靠来源支持 | [Link](https://longbridge.com/en/news/276479545.md) | | “我是一个孤独者”：我今年 62 岁，拥有数百万美元的投资组合，但没有继承人。我是否应该在晚年寻找一位妻子？ | 一位 62 岁的男性拥有数百万美元的投资组合且没有继承人，他正在考虑是否在晚年为了陪伴和照顾而结婚。他已将自己的遗产指定给他的高中，并寻求关于任命遗嘱执行人和持久授权书的建议。回应强调了为老年财务独立进行规划的重要性，建议购买长期护理保险， | [Link](https://longbridge.com/en/news/276256572.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.